LUMUS trial did not meet its primary and secondary endpoints in the overall trial population – – Robust responses in the prespecified subgroup of patients with high interferon gene signature (IFNGS-hi ...
Remaining 2026 capital expenditure investment will support additional new locations and planned store renovations as Loblaw ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results